 | • レポートコード：MRC23Q35924 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、88ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の皮膚T細胞リンパ腫市場について調査・分析し、世界の皮膚T細胞リンパ腫市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（放射線治療、幹細胞移植、局所化学療法、化学療法、免疫療法）、用途別セグメント分析（病院、外来手術センター、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Bristol-Myers Squibb Company、Bausch Health Companies、Kyowa Hakko Kirin、Seattle Genetics、Merck、Elorac、Actelion pharmaceuticalsなどが含まれています。 世界の皮膚T細胞リンパ腫市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、皮膚T細胞リンパ腫市場規模を推定する際に考慮しました。本レポートは、皮膚T細胞リンパ腫の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、皮膚T細胞リンパ腫に関するビジネス上の意思決定に役立てることを目的としています。 ・皮膚T細胞リンパ腫市場の概要 - 皮膚T細胞リンパ腫のタイプ別セグメント - 世界の皮膚T細胞リンパ腫市場規模：タイプ別分析（放射線治療、幹細胞移植、局所化学療法、化学療法、免疫療法） - 皮膚T細胞リンパ腫の用途別セグメント - 世界の皮膚T細胞リンパ腫市場規模：用途別分析（病院、外来手術センター、その他） - 世界の皮膚T細胞リンパ腫市場規模予測（2018年-2029年） ・皮膚T細胞リンパ腫市場の成長トレンド - 皮膚T細胞リンパ腫の地域別市場規模（2018年-2029年） - 皮膚T細胞リンパ腫市場ダイナミクス - 皮膚T細胞リンパ腫の業界動向 - 皮膚T細胞リンパ腫市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：放射線治療、幹細胞移植、局所化学療法、化学療法、免疫療法 - 世界の皮膚T細胞リンパ腫のタイプ別市場規模（2018年-2023年） - 世界の皮膚T細胞リンパ腫のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、外来手術センター、その他 - 世界の皮膚T細胞リンパ腫の用途別市場規模（2018年-2023年） - 世界の皮膚T細胞リンパ腫の用途別市場規模（2024年-2029年） ・皮膚T細胞リンパ腫の地域別市場規模 - 北米の皮膚T細胞リンパ腫市場規模（2018年-2029年） - アメリカの皮膚T細胞リンパ腫市場規模（2018年-2029年） - ヨーロッパの皮膚T細胞リンパ腫市場規模（2018年-2029年） - アジア太平洋の皮膚T細胞リンパ腫市場規模（2018年-2029年） - 中国の皮膚T細胞リンパ腫市場規模（2018年-2029年） - 日本の皮膚T細胞リンパ腫市場規模（2018年-2029年） - 韓国の皮膚T細胞リンパ腫市場規模（2018年-2029年） - インドの皮膚T細胞リンパ腫市場規模（2018年-2029年） - オーストラリアの皮膚T細胞リンパ腫市場規模（2018年-2029年） - 中南米の皮膚T細胞リンパ腫市場規模（2018年-2029年） - 中東・アフリカの皮膚T細胞リンパ腫市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Bristol-Myers Squibb Company、Bausch Health Companies、Kyowa Hakko Kirin、Seattle Genetics、Merck、Elorac、Actelion pharmaceuticals ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Cutaneous Tcell Lymphoma market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Cutaneous Tcell Lymphoma is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Cutaneous Tcell Lymphoma is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Cutaneous Tcell Lymphoma in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Cutaneous Tcell Lymphoma include Bristol-Myers Squibb Company, Bausch Health Companies, Kyowa Hakko Kirin, Seattle Genetics, Merck, Elorac and Actelion pharmaceuticals, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cutaneous Tcell Lymphoma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cutaneous Tcell Lymphoma.
The Cutaneous Tcell Lymphoma market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cutaneous Tcell Lymphoma market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cutaneous Tcell Lymphoma companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Bristol-Myers Squibb Company
Bausch Health Companies
Kyowa Hakko Kirin
Seattle Genetics
Merck
Elorac
Actelion pharmaceuticals
Segment by Type
Radiation Therapy
Stem Cell Transplantation
Topical Chemotherapy
Chemotherapy
Immuno Therapy
Segment by Application
Hospital
Ambulatory Surgery Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cutaneous Tcell Lymphoma companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cutaneous Tcell Lymphoma Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Radiation Therapy
1.2.3 Stem Cell Transplantation
1.2.4 Topical Chemotherapy
1.2.5 Chemotherapy
1.2.6 Immuno Therapy
1.3 Market by Application
1.3.1 Global Cutaneous Tcell Lymphoma Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Ambulatory Surgery Center
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cutaneous Tcell Lymphoma Market Perspective (2018-2029)
2.2 Cutaneous Tcell Lymphoma Growth Trends by Region
2.2.1 Global Cutaneous Tcell Lymphoma Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Cutaneous Tcell Lymphoma Historic Market Size by Region (2018-2023)
2.2.3 Cutaneous Tcell Lymphoma Forecasted Market Size by Region (2024-2029)
2.3 Cutaneous Tcell Lymphoma Market Dynamics
2.3.1 Cutaneous Tcell Lymphoma Industry Trends
2.3.2 Cutaneous Tcell Lymphoma Market Drivers
2.3.3 Cutaneous Tcell Lymphoma Market Challenges
2.3.4 Cutaneous Tcell Lymphoma Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cutaneous Tcell Lymphoma Players by Revenue
3.1.1 Global Top Cutaneous Tcell Lymphoma Players by Revenue (2018-2023)
3.1.2 Global Cutaneous Tcell Lymphoma Revenue Market Share by Players (2018-2023)
3.2 Global Cutaneous Tcell Lymphoma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cutaneous Tcell Lymphoma Revenue
3.4 Global Cutaneous Tcell Lymphoma Market Concentration Ratio
3.4.1 Global Cutaneous Tcell Lymphoma Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cutaneous Tcell Lymphoma Revenue in 2022
3.5 Cutaneous Tcell Lymphoma Key Players Head office and Area Served
3.6 Key Players Cutaneous Tcell Lymphoma Product Solution and Service
3.7 Date of Enter into Cutaneous Tcell Lymphoma Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cutaneous Tcell Lymphoma Breakdown Data by Type
4.1 Global Cutaneous Tcell Lymphoma Historic Market Size by Type (2018-2023)
4.2 Global Cutaneous Tcell Lymphoma Forecasted Market Size by Type (2024-2029)
5 Cutaneous Tcell Lymphoma Breakdown Data by Application
5.1 Global Cutaneous Tcell Lymphoma Historic Market Size by Application (2018-2023)
5.2 Global Cutaneous Tcell Lymphoma Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Cutaneous Tcell Lymphoma Market Size (2018-2029)
6.2 North America Cutaneous Tcell Lymphoma Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Cutaneous Tcell Lymphoma Market Size by Country (2018-2023)
6.4 North America Cutaneous Tcell Lymphoma Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cutaneous Tcell Lymphoma Market Size (2018-2029)
7.2 Europe Cutaneous Tcell Lymphoma Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Cutaneous Tcell Lymphoma Market Size by Country (2018-2023)
7.4 Europe Cutaneous Tcell Lymphoma Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cutaneous Tcell Lymphoma Market Size (2018-2029)
8.2 Asia-Pacific Cutaneous Tcell Lymphoma Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Cutaneous Tcell Lymphoma Market Size by Region (2018-2023)
8.4 Asia-Pacific Cutaneous Tcell Lymphoma Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cutaneous Tcell Lymphoma Market Size (2018-2029)
9.2 Latin America Cutaneous Tcell Lymphoma Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Cutaneous Tcell Lymphoma Market Size by Country (2018-2023)
9.4 Latin America Cutaneous Tcell Lymphoma Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cutaneous Tcell Lymphoma Market Size (2018-2029)
10.2 Middle East & Africa Cutaneous Tcell Lymphoma Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Cutaneous Tcell Lymphoma Market Size by Country (2018-2023)
10.4 Middle East & Africa Cutaneous Tcell Lymphoma Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb Company
11.1.1 Bristol-Myers Squibb Company Company Detail
11.1.2 Bristol-Myers Squibb Company Business Overview
11.1.3 Bristol-Myers Squibb Company Cutaneous Tcell Lymphoma Introduction
11.1.4 Bristol-Myers Squibb Company Revenue in Cutaneous Tcell Lymphoma Business (2018-2023)
11.1.5 Bristol-Myers Squibb Company Recent Development
11.2 Bausch Health Companies
11.2.1 Bausch Health Companies Company Detail
11.2.2 Bausch Health Companies Business Overview
11.2.3 Bausch Health Companies Cutaneous Tcell Lymphoma Introduction
11.2.4 Bausch Health Companies Revenue in Cutaneous Tcell Lymphoma Business (2018-2023)
11.2.5 Bausch Health Companies Recent Development
11.3 Kyowa Hakko Kirin
11.3.1 Kyowa Hakko Kirin Company Detail
11.3.2 Kyowa Hakko Kirin Business Overview
11.3.3 Kyowa Hakko Kirin Cutaneous Tcell Lymphoma Introduction
11.3.4 Kyowa Hakko Kirin Revenue in Cutaneous Tcell Lymphoma Business (2018-2023)
11.3.5 Kyowa Hakko Kirin Recent Development
11.4 Seattle Genetics
11.4.1 Seattle Genetics Company Detail
11.4.2 Seattle Genetics Business Overview
11.4.3 Seattle Genetics Cutaneous Tcell Lymphoma Introduction
11.4.4 Seattle Genetics Revenue in Cutaneous Tcell Lymphoma Business (2018-2023)
11.4.5 Seattle Genetics Recent Development
11.5 Merck
11.5.1 Merck Company Detail
11.5.2 Merck Business Overview
11.5.3 Merck Cutaneous Tcell Lymphoma Introduction
11.5.4 Merck Revenue in Cutaneous Tcell Lymphoma Business (2018-2023)
11.5.5 Merck Recent Development
11.6 Elorac
11.6.1 Elorac Company Detail
11.6.2 Elorac Business Overview
11.6.3 Elorac Cutaneous Tcell Lymphoma Introduction
11.6.4 Elorac Revenue in Cutaneous Tcell Lymphoma Business (2018-2023)
11.6.5 Elorac Recent Development
11.7 Actelion pharmaceuticals
11.7.1 Actelion pharmaceuticals Company Detail
11.7.2 Actelion pharmaceuticals Business Overview
11.7.3 Actelion pharmaceuticals Cutaneous Tcell Lymphoma Introduction
11.7.4 Actelion pharmaceuticals Revenue in Cutaneous Tcell Lymphoma Business (2018-2023)
11.7.5 Actelion pharmaceuticals Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details